Functions of 5-HT 2A receptor and its antagonists in the cardiovascular system

Pharmacology and Therapeutics

Volumn 104, Issue 1, 2004, Pages 59-81

  Nagatomo, Takafumi ^a   Rashid, Mamunur ^b   Abul Muntasir, Habib ^a   Komiyama, Tadazumi ^a  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b UNIVERSITY OF RAJSHAHI   (Bangladesh)

Author keywords

5 HT; 5 HT 2A; 5 HT 2A antagonists; Cardiovascular diseases; Sarpogrelate

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; 1 [2 [4 (4 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N METHYLISOCHROMAN 6 CARBOXAMIDE; 3 (1,2,5,6 TETRAHYDRO 4 PYRIDYL)PYRROLO[3,2 B]PYRIDIN 5 ONE; 3 [2 [2 (4 METHYL 1 PIPERIDINYL)ETHYL] 1 PYRROLIDINESULFONYL]PHENOL; 3 [4 (3 CHLOROPHENYL) 1 PIPERAZINYL] 1,1 DIPHENYL 2 PROPANOL; 3,N DIMETHYL N [1 METHYL 3 (4 METHYL 1 PIPERIDINYL)PROPYL]BENZENESULFONAMIDE; 5 (4 FLUOROBENZAMIDO) 3 (1 METHYL 4 PIPERIDINYL) 1H INDOLE FUMARATE; 5 CHLORO N [4 METHOXY 3 (1 PIPERAZINYL)PHENYL] 3 METHYL 2 BENZOTHIOPHENESULFONAMIDE; 8 [2 [(2,3 DIHYDRO 1,4 BENZODIOXIN 2 YL)METHYLAMINO]ETHYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE; 8 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE; ARA 000002; B 20991; BEMESETRON; CALMODULIN; CP 135807; CYCLIC AMP; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; N (3 DIMETHYLAMINO 2,3,4,9 TETRAHYDRO 1H CARBAZOL 6 YL) 4 FLUOROBENZAMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [4 [5 [3 (2 AMINOETHYL) 1H INDOL 5 YL] 1,2,4 OXADIAZOL 3 YL]BENZYL]METHANESULFONAMIDE; NAS 181; PHOSPHOLIPASE A2; PHOSPHOLIPASE C; PHOSPHOLIPASE D; R 102444; RAMOSETRON; RO 046790; RO 630563; RS 39604; SARPOGRELATE; SB 656104A; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 1E RECEPTOR; SEROTONIN 1F RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN 4 RECEPTOR; SEROTONIN 5 RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN 7 RECEPTOR; SL 650472; STAT PROTEIN; TS 951; UNINDEXED DRUG; YM 31636; SEROTONIN ANTAGONIST;

BINDING AFFINITY; CARDIOVASCULAR SYSTEM; CELLULAR DISTRIBUTION; DRUG BINDING; DRUG POTENCY; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; HEMODYNAMIC MONITORING; HEMODYNAMICS; HUMAN; LIGAND BINDING; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; THROMBOCYTE AGGREGATION; VASOCONSTRICTION; VASODILATATION; ANIMAL; CARDIOVASCULAR DISEASE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PHYSIOLOGY; PROTEIN BINDING;

ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; PROTEIN BINDING; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN ANTAGONISTS;

EID: 6944222950     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2004.08.005     Document Type: Review

References (242)

1. D. Abramowski, M. Rigo, D. Duc, D. Hoyer, and M. Staufenbiel Localization of the 5-hydroxytryptamine2C receptor protein in human and rat brain using specific antisera Neuropharmacology 34 1995 1635 1645
2. N. Adam, L.A. Borden, L.E. Schechter, E.L. Gustafson, T.L. Cochran, and P.J.J. Vaysse Cell-specific coupling of the cloned human 5-HT1F receptor to multiple signal transduction pathways Naunyn-Schmiedeberg's Arch Pharmacol 348 1993 566 575
3. D. Akin, and H. Gurdal Involvement of 5-HT1B and 5-HT1D receptors in sumatriptan mediated vasocontractile response in rabbit common carotid artery. 4 Br J Pharmacol 136 2 2002 177 182
4. N. Almaula, B.J. Ebersole, D. Zhang, H. Weinstein, and S.C. Sealfon Mapping the binding site pocket of the serotonin 5-hydroxytryptamine2A receptor. Ser3.36(159) provides a second interaction site for the protonated amine of serotonin but not of lysergic acid diethylamide or bufotenin J Biol Chem 271 25 1996 14672 14675
5. 4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle Naunyn-Schmiedeberg's Arch Pharmacol 363 2001 146 160
6. T. Back, R. Prado, W. Zhao, B.D. Watson, and M.D. Ginsberg Ritanserin, a 5-HT2 receptor antagonist, increases subcortical blood flow following photothrombotic middle cerebral artery occlusion in rats Neurol Res 20 7 1998 643 647
7. 2 receptor stimulation on excessive grooming, penile erection and plasma oxytocin concentrations Eur J Pharmacol 229 1992 9 14
8. J.A. Ballesteros, and H. Weinstein Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors Methods Neurosci 25 1995 366 428
9. A.K. Banes, and S.W. Watts Arterial expression of 5-HT2B and 5-HT1B receptors during development of DOCA-salt hypertension BMC Pharmacol 3 1 2003 12
10. R.A. Bantick, E.A. Rabiner, E. Hirani, M.H. de Vries, S.P. Hume, and P.M. Grasby Occupancy of agonist drugs at the 5-HT1A receptor Neuropsychopharmacology 29 5 2004 847 859
11. F. Barbe, E. Gautier, J.P. Bidouard, A. Grosset, S.E. O'Connor, and P. Janiak SL 65.0472 blocks 5-hydroxytryptamine-induced vasoconstriction in a dog hindlimb ischemia model Eur J Pharmacol 474 1 2003 117 120
12. M. Barros, E.L. Mello, R.S. Maior, C.P. Muller, M.A. de Souza Silva, and R.J. Carey Anxiolytic-like effects of the selective 5-HT1A receptor antagonist WAY 100635 in non-human primates Eur J Pharmacol 482 1-3 2003 197 203
13. 2A receptor-mediated out-ward current in C6 glioma cells is mimicked by intracellular IP3 release NeuroReport 5 1994 1245 1248
14. G. Baxter, G.A. Kennett, F. Blaney, and T. Blackburn 5-HT2 receptor subtypes: a family re-united? Trends Pharmacol Sci 16 1995 105 110
15. 1D receptor binding affinity of 5-hydroxytryptamine, 5-carboxamidotryptamine and sumatriptan in the central nervous system of seven species Eur J Pharmacol 213 1992 193 197
16. K.A. Berg, W.P. Clarke, Y. Chen, B.J. Ebersole, R.D. Mckay, and S. Maayani 5-Hydroxytryptamine type 2A receptors regulate cyclic AMP accumulation in a neuronal cell line by protein kinase C-dependent and calcium/calmodulin- dependent mechanisms Mol Pharmacol 45 1994 826 836
17. M.J. Bickerdike 5-HT2C receptor agonists as potential drugs for the treatment of obesity Curr Top Med Chem 3 8 2003 885 897
18. 3 receptor antagonists ICS 205930 Life Sci 43 1988 1441 1449
19. W.W. Blessing 5-Hydroxytryptamine 1A receptor activation reduces cutaneous vasoconstriction and fever associated with the acute inflammatory response in rabbits Neuroscience 123 1 2004 1 4
20. P. Blier, B. Seletti, F. Gilbert, S.N. Young, and C. Benkelfat Serotonin 1A receptor activation and hypothermia in humans: lack of evidence for a presynaptic mediation Neuropsychopharmacology 27 2 2002 301 308
21. A.C. Bolte, J. van Eyck, R.J. Strack van Schijndel, H.P. van Geijn, and G.A. Dekker The haemodynamic effects of ketanserin versus dihydralazine in severe early-onset hypertension in pregnancy Br J Obstet Gynaecol 105 7 1998 723 731
22. 2C receptors Br J Pharmacol 115 1995 622 628
23. D. Brasil, R.M. Temsah, K. Kumar, H. Kumamoto, N. Takeda, and N.S. Dhalla Blockade of 5-HT(2A) receptors by sarpogrelate protects the heart against myocardial infarction in rats J Cardiovasc Pharmacol Ther 7 2002 53 59
24. S.J. Briddon, R.A. Leslie, and J.M. Elliott Comparative desensitization of the human 5-HT2A and 5-HT2C receptors expressed in the human neuro blastoma cell line SH-SY5Y Br J Pharmacol 125 1988 727 734
25. R.N. Brogden, and E.M. Sorkin Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease Drugs 40 1990 903 949
26. S.M. Bromidge, A.M. Brown, S.E. Clarke, K. Dodgson, T. Gager, and H.L. Grassam 5-Chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)-3-methyl-2- benzothiophenesulfon-amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist J Med Chem 42 2 1999 202 205
27. A.T. Bruinvels, B. Landwehrmeyer, C. Waeber, J.M. Palacios, and D. Hoyer Homogeneous 5-HT1D recognition sites in the human substantia nigra identified with a new iodinated radioligand Eur J Pharmacol 202 1991 89 91
28. A.G. Caicoya, M.E. Beneytez, M. Delgado, J. Manzanares, M.L. Lopez-Rodriguez, and B. Benhamu Biochemical, electrophysiological and neurohormonal studies with B-20991, a selective 5-HT1A receptor agonist Pharmacology 62 4 2001 234 242
29. G. Campiani, E. Morelli, S. Gemma, V. Nacci, S. Butini, and M. Hamon Pyrroloquinoxaline derivatives as high-affinity and selective 5-HT(3) receptor agonists: synthesis, further structure-activity relationships, and biological studies J Med Chem 42 21 1999 4362 4379
30. D. Cartier, I. Lihrmann, F. Parmentier, C. Bastard, J. Bertherat, and P. Caron Overexpression of serotonin4 receptors in cisapride-responsive adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia causing Cushing's syndrome J Clin Endocrinol Metab 88 1 2003 248 254
31. 1A receptor agonist, reduces the immobility of rats in the forced swimming test by acting on the raphe dorsalis Eur J Pharmacol 158 1988 53 59
32. J.C. Chambard, E. van Obberghen-Scilling, R.J. Haslam, V. Vouret, and J. Pouyssegur Chinese hamster serotonin (5HT) type 2 receptor cDNA sequence Nucleic Acids Res 18 1990 5282
33. 2 receptor is encoded by a multiple intron-exon gene Mol Brain Res 14 1992 20 26
34. 2A receptor binding sites in cerebellar granule neurons: involvement of calcium influx and a calmodulin-dependent pathway J Pharmacol Exp Ther 275 1995 674 680
35. D.S. Choi, and L. Maroteaux Immunohistochemical localisation of the serotonin 5-HT2B receptor in mouse gut, cardiovascular system, and brain FEBS Lett 391 1-2 1996 45 51
36. D.S. Choi, S.J. Ward, N. Messaddeq, J.M. Launay, and L. Maroteaux 5-HT2B receptor-mediated serotonin morphogenetic functions in mouse cranial neural crest and myocardiac cells Development 124 9 1997 1745 1755
37. M.S. Choudhary, N. Sachs, A. Uluer, R.A. Glennon, R.B. Westkaemper, and B.L. Roth Differential ergoline and ergopeptine binding to 5-hydroxytryptamine2A receptors: ergoline require an aromatic residue at position 340 for high affinity binding. Mol Pharmacol 47 1995 450 457
38. M.L. Cohen, and L.A. Fludzinski Contractile serotonergic receptor in rat stomach fundus J Pharmacol Exp Ther 243 1987 264 269
39. 2 receptors mediating contraction in vascular smooth muscle J Pharmacol Exp Ther 218 1981 421 425
40. 2 receptor activation Eur J Pharmacol 161 1989 91 94
41. H.E. Connor, C.M. Stubbs, W. Feniuk, and P.P. Humphrey Effect of sumatriptan, a selective 5-HT1-like receptor agonist, on pial vessel diameter in anaesthetised cats J Cereb Blood Flow Metab 12 3 1992 514 519
42. F.M. Cutrer, X.J. Yu, G. Ayata, M.A. Moskowitz, and C. Waeber Effects of PNU-109, 291, a selective 5-HT1D receptor agonist, on electrically induced dural plasma extravasation and capsaicin-evoked c-fos immunoreactivity within trigeminal nucleus caudalis Neuropharmacology 38 7 1999 1043 1053
43. E. De Castro-e-Silva, C. Sarmento, T.A. Nascimento, C.P. Luz, T. Soares, and A. Marinho Effect of third ventricle administration of l-694,247, a selective 5-HT1D receptor agonist, on water intake in rats Pharmacol Biochem Behav 57 4 1997 749 754
44. 2 receptor sites J Biol Chem 260 1985 7603 7608
45. F. De Clerk, J.L. David, and P.A. Janssen Inhibition of 5-hydroxytryptamine-induced and-amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist Agents Actions 12 1982 388 397
46. L. De Groote, A.A. Klompmakers, B. Olivier, and H.G. Westenberg An evaluation of the effect of NAS-181, a new selective 5-HT(1B) receptor antagonist, on extracellular 5-HT levels in rat frontal cortex Naunyn-Schmiedebergs Arch Pharmacol 367 2 2003 89 94 (Epub 2003 Jan 24)
47. P. De Vries, A. Sanchez-Lopez, D. Centurion, J.P. Heiligers, P.R. Saxena, and C.M. Villalon The canine external carotid vasoconstrictor 5-HT1 receptor: blockade by 5-HT1B (SB224289), but not by 5-HT1D (BRL15572) receptor antagonists Eur J Pharmacol 362 1 1998 69 72
48. G. Domenighetti, P. Leuenberger, and F. Feihl Haemodynamic effects of ketanserin either alone or with oxygen in COPD patients with secondary pulmonary hypertension Monaldi Arch Chest Dis 52 5 1997 429 433
49. (1A) receptor agonist flesinoxan with that of 8-OH-DPAT in the rat Eur J Pharmacol 180 1990 339 349
50. W.M. Du, C.Y. Miao, J.G. Liu, F.M. Shen, X.Q. Yang, and D.F. Su Effects of long-term treatment with ketanserin on blood pressure variability and end-organ damage in spontaneously hypertensive rats J Cardiovasc Pharmacol 41 2 2003 233 239
51. 2-like receptor Am J Physiol 266 1994 R284 R291
52. 2A receptor determines relative efficacy Mol Pharmacol 63 1 2003 36 43
53. 2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs J Pharmacol Exp Ther 286 1 1998 85 90
54. 1C receptors in choroids plexus epithelium J Neurosci 12 1992 4775 4782
55. M. Fernandez, P. Pizcueta, J.C. Garcia-Pagan, F. Feu, I. Cirera, and J. Bosch Effects of ritanserin, a selective and specific S2-serotonergic antagonist, on portal pressure and splanchnic hemodynamics in rats with long-term bile duct ligation Hepatology 18 2 1993 389 393
56. S.A. Filla, B.M. Mathes, K.W. Johnson, L.A. Phebus, M.L. Cohen, and D.L. Nelson J Med Chem 46 14 2003 3060 3071
57. C. Finizia, L. Lundell, L. Cange, and M. Ruth The effect of cisapride on oesophageal motility and lower sphincter function in patients with gastro-oesophageal reflux disease Eur J Gastroenterol Hepatol 14 1 2002 9 14
58. 2A receptor signal transduction J Pharmacol Exp Ther 284 1998 346 355
59. M. Foguet, D. Hoyer, L.A. Pardo, A. Parekh, F.W. Kluxen, and H.O. Kalkman Cloning and functional characterization of the rat stomach fundus serotonin receptor EMBO J 11 1992 3481 3487
60. M. Foguet, H. Nguyen, H. Le, and H. Lubbert Structure of the mouse 5-HT1C, 5-HTT2 and stomach fundus serotonin receptor genes NeuroReport 3 1992 345 348
61. W.H. Frishmann, and P. Grewall Serotonin and the heart Ann Med 32 2000 195 209
62. 3 receptors J Physiol 544 2002 897 912
63. T. Fujiwara, and S. Chiba Augmented responses to 5-HT2-receptor-mediated vasoconstrictions in atherosclerotic rabbit common carotid arteries J Cardiovasc Pharmacol 26 3 1995 503 510
64. V. Fuster, L. Badimon, J.J. Badimon, and J.H. Chesebro The pathogenesis of coronary artery disease and the acute coronary syndromes (part 1) N Engl J Med 326 1992 242 250
65. 2A receptors expressed in rat renal mesangial cells inhibit cyclic AMP accumulation Mol Pharmacol 48 1995 230 237
66. 1A agonist 8-hydroxy-2-di-n-propylaminotetralin-8-OH-DPAT Eur J Pharmacol 154 1988 339 342
67. 2B receptors Br J Pharmacol 130 2000 692 698
68. P.J. Goadsby Migraine: diagnosis and management Intern Med J 33 9-10 2003 436 442
69. D.J. Goldstein, K.I. Roon, W.W. Offen, N.M. Ramadan, L.A. Phebus, and K.W. Johnson Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial Lancet 13; 358 9289 2001 1230 1234
70. P. Golino, F. Piscione, C.R. Benedict, H.V. Anderson, M. Cappelli-Bigazzi, and C. Indolfi Local effect of serotonin released during coronary angioplasty N Engl J Med 330 1994 523 528
71. H. Gong, T. Nakamura, K. Hattori, T. Ohnuki, M. Rashid, and M. Nakazawa A novel 5-HT(2) antagonist, sarpogrelate hydrochloride, shows inhibitory effects on both contraction and relaxation mediated by 5-HT receptor subtypes in porcine coronary arteries Pharmacology 61 2000 263 268
72. 2+/calmodulin-dependent kinase Biochem. J. 339 1999 329 334
73. 2 generation in rat renal mesangial cells Am J Physiol Renal Physiol 278 2000 F650 F658
74. 2A receptor induces TGF-β1 expression in mesangial cells via ERK: proliferative and fibrotic signals Am J Physiol 276 1999 F922 F930
75. 2C receptors revealed by heterologous expression Naunyn-Schmiedeberg's Arch Pharmacol 359 1999 21 27
76. 2) receptor antagonists in ischemic rat hearts J Cardiovasc Pharmacol 22 1993 664 672
77. 2A receptor coupled to the Jak/STAT pathway J Biol Chem 272 1997 14825 14829
78. M.R. Guscott, E. Egan, G.P. Cook, J.A. Stanton, M.S. Beer, and T.W. Rosahl The hypothermic effect of 5-CT in mice is mediated through the 5-HT7 receptor Neuropharmacology 44 8 2003 1031 1037
79. 2+ channels Neurochem Int 32 1998 153 162
80. 2-serotonergic receptor antagonist Thromb Haemost 65 1991 415 420
81. H. Hara, A. Kitajima, H. Shimada, and Y. Tamao Antithrombic effect of MCI-9042, a new antiplatelet agent on experimental thrombosis models Thromb Haemost 66 1991 484 488
82. P.R. Hartig, T.A. Branchek, and R.L. Weinshak A subfamily of 5-HT1D receptor genes Trends Pharmacol Sci 13 1992 152 159
83. T. Hayashi, D. Sumi, H. Matsui-Hirai, A. Fukatsu, P.J. Arockia Rani, and H. Kano Sarpogrelate HCl, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism Atherosclerosis 168 1 2003 23 31
84. L.K. Heisler, H.M. Chu, and L.H. Tecott Epilepsy and obesity in serotonin 5-HT2C receptor mutant mice Ann N Y Acad Sci 15 861 1998 74 78
85. 1D receptor in rat and human brain J Neurochem 50 1988 1624 1631
86. 1A binding sites Eur J Pharmacol 12 1987 279 282
87. 1A receptor ligands with different pharmacological properties Drugs Future 15 1990 159 170
88. M. Hibert, S. Trumpp-Kallmeyer, A. Bruinvels, and J. Hoflack Three-dimensional models of neurotransmitter G-binding protein-coupled receptors Mol Pharmacol 40 1991 8 15
89. (1A)-receptor antagonist J Med Chem 33 1990 1541 1544
90. E. Hironaka, M. Hongo, A. Sakai, E. Mawatari, F. Terasawa, and N. Okumura Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats Cardiovasc Res 60 3 2003 692 699
91. H. Holmsen Platelet activation and serotonin P.M. Vanhoutte Serotonin and The Cardiovascular System 1985 Raven Press New York, NY 75 86
92. S. Hood, D. Birnie, A. Nasser, and W.S. Hillis Effect of ketanserin on central haemodynamics and coronary circulation J Cardiovasc Pharmacol 32 6 1998 983 987
93. D. Hoyer 5-Hydroxytryptamine receptors and effector coupling mechanisms in peripheral tissues J.R. Fozard Peripheral Actions of 5-HT 1989 Oxford University Press Oxford 72 99
94. D. Hoyer, and G.R. Martin Classification and nomenclature of 5-HT receptors: a comment on current issues Behav Brain Res 73 1996 263 268
95. D. Hoyer, and D.N. Middlemis Species differences in the pharmacology of terminal 5-HT autoreceptors in mammalian brain TIPS 10 1989 130 132
96. 1D receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in calf substansia nigra Eur J Pharmacol 147 1988 145 147
97. 1B recognition sites Brain Res 376 1986 85 96
98. D. Hoyer, D.E. Clarke, J.R. Fozard, P.R. Hartig, G.R. Martin, and E.J. Mylecharane VII. International union of pharmacology classification of receptors of 5-hydroxytryptamine (serotonin) Pharmacol Rev 46 1994 157 203
99. T.J. Hudzik, M. Yanek, T. Porrey, J. Evenden, C. Paronis, and M. Mastrangelo Behavioral pharmacology of AR-A000002, a novel, selective 5-hydroxytryptamine(1B) antagonist J Pharmacol Exp Ther 304 3 2003 1072 1084
100. P.P.A. Humphery, W. Feniuk, M.J. Perren, I.J.M. Beresford, and M. Skingle Serotonin and migraine P.M. Whitaker-Azmitia S.J. Peroutka The Pharmacology of Serotonin 1990 New York Academy of Sciences New York 587 600
101. S. Ichida, T. Hayashi, and M. Terao Selective inhibition by ketanserin and spiroperidol of 5-HT-induced myometrial contraction Eur J Pharmacol 96 1983 155 158
102. K. Ikeda, K. Tojo, G. Tokudome, T. Hosoya, M. Harada, and K. Nakao The effects of sarpogrelate on cardiomyocyte hypertrophy Life Sci 67 2000 2991 2996
103. T. Ishida, S. Kawashima, K. Hirata, T. Sakoda, Y. Shimokawa, and Y. Miwa Serotonin-induced hypercontraction through 5-hydroxytryptamine 1B receptors in atherosclerotic rabbit coronary arteries Circulation 103 2001 1289 1295
104. T. Ishine, I. Bouchelet, E. Hamel, and T.J. Lee Serotonin 5-HT(7) receptors mediate relaxation of porcine pial veins Am J Physiol Heart Circ Physiol 278 3 2000 H907 H912
105. K. Ito, and T. Notsu Effect of sarpogrelate hydrochloride (MCI-9042) on peripheral circulation of chronic arterial occlusive diseases J Clin Ther Med 7 1991 1243 1251
106. H. Ito, T. Kiso, K. Miyata, T. Kamato, H. Yuki, and S. Akuzawa Pharmacological profile of YM-31636, a novel 5-HT3 receptor agonist, in vitro Eur J Pharmacol 409 2 2000 195 201
107. T.O. Jalonen, R.R. Margraf, D.B. Weilt, C.J. Charniga, M.L. Linne, and H.K. Kimelberg Serotonin induces inward potassium and calcium currents in rat cortical astrocytes Brain Res 758 1997 69 82
108. 2 receptor blockade to study serotonin-induced pathology Trends Pharmacol Sci 4 1983 198 206
109. D. Julius, A.B. MacDermott, R. Axel, and T.M. Jessell Molecular characterization of a functional cDNA encoding the serotonin 1c receptor Science 241 1988 558 564
110. S. Kajita, C. Ito, R. Kawamura, S. Yasuda, Y. Isobe, and K. Fukushima Pharmacological characterization of a novel 5-HT4 receptor agonist, TS-951, in vitro Pharmacology 63 1 2001 8 16
111. K. Kannari, K. Kurahashi, M. Tomiyama, T. Maeda, A. Arai, and M. Baba Tandospirone citrate, a selective 5-HT1A agonist, alleviates l-DOPA-induced dyskinesia in patients with Parkinson's disease No To Shinkei 54 2 2002 133 137
112. S. Kato, I. Kishiro, M. Machida, D. Fuse, T. Yoshida, and N. Kaneko Suppressive effect of sarpogrelate hydrochloride on respiratory failure and right ventricular failure with pulmonary hypertension in patients with systemic sclerosis J Intern Med Res 28 2000 258 268
113. H. Kihara, K. Hirose, H. Koganei, N. Sasaki, H. Yamamoto, and A. Kimura AT-1-15, a novel serotonin (5-HT) 2 receptor antagonist, blocks vascular and platelet 5-HT2A receptors and prevents the laurate-induced peripheral vascular lesion in rats J Cardiovasc Pharmacol 35 4 2000 523 530
114. 2A receptor antagonist, in rat arterial thrombosis model and its effect on bleeding time Eur J Pharmacol 433 2001 147 162
115. R. Kikumoto, H. Hara, K. Ninomiya, M. Osakabe, M. Sugano, and H. Fukami Syntheses and platelet aggregation inhibitory and antithrombic properties of [2-[(omega-aminoalkoxy)phenyl]ethyl]benzenes J Med Chem 33 1990 1818 1823
116. T. Kinugawa, M. Fujita, J.D. Lee, H. Nakajima, H. Hanada, and S. Miyamoto Effectiveness of a novel serotonin blocker, sarpogrelate, for patients with angina pectoris Am Heart J 144 2 2002 E1
117. T. Komatsu, K. Kitazawa, O. Izawa, S. Inoue, M. Ohshima, and S. Iida Study of the metabolic fate of ((±)-2-(dimethylamino)-1-[[o-(m- methoxyphenethyl)-phenoxy]-methyl]ethyl hydrogen succinate hydrochloride (MCI-9042): (I). Metabolism of MCI-9042 in rats, dogs, monkeys and human Yakubutsu Dotai 6 1992 353 375 (CA 116, 50810y)
118. T. Komiyama, H. Kihara, K. Hirose, R. Yoshimoto, and H. Shigematsu AT-1015, a novel serotonin2A receptor antagonist, improves resaturation of exercised ischemic muscle in hypercholesterolemic rabbits J Vasc Surg 39 3 2004 661 667
119. 2 activation: the involvement of MAP kinases J Neurochem 86 2003 980 991
120. 2 signaling pathways have different receptor reserves J Pharmacol Exp Ther 304 1 2003 229 237
121. 2B receptor Mol Pharmacol 46 1994 227 234
122. Z.S. Kyriakides, E. Sbarouni, N. Nikolaou, A. Antoniadis, and D.T. Kremastinos Intracoronary ketanserin augments coronary collateral blood flow and decreases myocardial ischemia during balloon angioplasty Cardiovasc Drugs Ther 13 5 1999 415 422
123. 2 receptors Life Sci 28 1981 1015 1022
124. J.E. Leysen, D. De Chaffoy De Courcelles, F. De Clerck, C.J.E. Niemegeers, and J.M. Van Nueten Serotonin-S2 receptor binding sites and functional correlates Neuropharmacology 23 1984 1493 1501
125. 2 antagonist Mol Pharmacol 27 1985 600 611
126. 1D in the rabbit and guinea-pig brain cortex Naunyn-Schmiedeberg's Arch Pharmacol 343 1991 353 364
127. 1 receptors and behaviour Neurosci Biobehav Rev 16 1992 83 93
128. T. Mach The brain-gut axis in irritable bowel syndrome - clinical aspects Med Sci Monit 10 6 2004 RA125 RA131 [Epub ahead of print]
129. M.R. MacLean, R.A. Clayton, A.G. Templeton, and I. Morecroft Evidence for 5-HT1-like receptor-mediated vasoconstriction in human pulmonary artery Br J Pharmacol 119 2 1996 277 282
130. 2B receptors: molecular modeling and site-directed mutagenesis J Biol Chem 277 2002 17170 17178
131. M. Mannelli, P. Ferruzzi, P. Luciani, C. Crescioli, L. Buci, and G. Corona Cushing's syndrome in a patient with bilateral macronodular adrenal hyperplasia responding to cisapride: An in vivo and in vitro study J Clin Endocrinol Metab 88 10 2003 4616 4622
132. R.S. Mansbach, C.C. Rovetti, and J.E. Macor CP-135,807, a selective 5-HT1D agonist: effects in drug discrimination and punishment procedures in the pigeon Psychopharmacology (Berl) 128 3 1996 313 319
133. 1B agonist and rationally restricted phenolic analogue of 5-methoxy-3-1,2,5,6-tetrahydropyrid-4-ylindole J Med Chem 33 1990 2087 2093
134. 3 receptor, a serotonin-gated ion channel Science 254 1991 432 437
135. K. Maruyama, J. Kinami, Y. Sugita, Y. Takada, E. Sugiyama, and H. Tsuchihashi MCI-9042: high affinity for serotonergic receptors as assessed by radioligand binding assay J Pharmacobiodyn 14 1991 177 181
136. 1D receptors in human cerebral cortex J Neurochem 60 1993 1179 1182
137. 1-like subtype Proc Natl Acad Sci U S A 89 1992 5517 5521
138. R. McCall, and M. Clement Role of serotonin 1A and serotonin 2 receptors in the central regulation of the cardiovascular system Pharmacol Rev 46 1994 231 243
139. C.M. Mckune, and S.W. Watts Characterization of the serotonin receptor mediating contraction in the mouse thoracic aorta and signal pathway coupling J Pharmacol Exp Ther 297 1 2001 88 95
140. D.S. McQueen, and A.K. Mir 5-Hydroxytryptamine and cardiopulmonary and carotid body reflex mechanisms J.R. Fozard The Peripheral Actions of 5-Hydroxytryptamine 1989 Oxford University Press Oxford, UK 301 326
141. H.Y. Meltzer, and M.T. Lowy The serotonin hypothesis of suppression H.Y. Meltzer Psychopharmacology: The Third Generation of Progress 1987 Raven press New York 513 526
142. 1C receptor mRNA in the rodent brain examined by in situ hybridization histochemistry. Comparison with receptor binding distribution Neuroscience 35 1990 577 591
143. C.Y. Miao, H.H. Xie, H. Yu, Z.X. Chu, and D.F. Su Ketanserin stabilizes blood pressure in conscious spontaneously hypertensive rats Clin Exp Pharmacol Physiol 30 3 2003 189 193
144. R. Mitchell, D. McCulloch, E. Lutz, M. Johnson, C. MacKenzie, and M. Fennell Rhodopsin-family receptors associate with small G proteins to activate phospholipase D Nature (Lond) 392 1998 411 414
145. K. Miyata, T. Kamato, and A. Nishida Pharmacological profile of (R)-5-[(1-methyl-3-indolyl)carbonyl]-4,5,6,7-tetrahydro-1H-benzimidazol hydrochloride (YM060), a potent and selective 5-hydroxytryptamine3 receptor antagonist, and its enantiomer in the isolated issue J Pharmacol Exp Ther 259 1991 15 21
146. 2A serotonergic receptor antagonist, inhibits serotonin-induced coronary artery spasm in a porcine model J Cardiovasc Pharmacol 35 2000 294 301
147. G.J. Molderings, G. Engel, E. Roth, and M. Gothert Characterization of an endothelial 5-hydroxytryptamine (5-HT) receptor mediating relaxation of the porcine coronary artery Naunyn-Schmiedeberg's Arch Pharmacol 340 1989 300 308
148. C. Montiel, C.J. Herrero, E. Garcia-Palomero, J. Renart, A.G. Garcia, and R.B. Lomax Serotonergic effects of dotarizine in coronary artery and in oocytes expressing 5-HT2 receptors Eur J Pharmacol 332 1997 183 193
149. H. Moro, J. Hayashi, H. Ohzeki, S. Eguchi, S. Nakazawa, and M. Terashima Clinical effect of sarpogrelate for the chronic arterial obliterans Jpn Phamacol Ther 25 1997 1807 1811
150. D.L. Murphy, C. Wichems, Qian Li, and A. Heils Molecular manipulations as tools for enhancing our understanding of 5-HT neurotransmission TIPS 20 1999 246 252
151. K. Nakamura, H. Kariyazono, Y. Moriyama, H. Toyohira, H. Kubo, and G. Yotsumoto Effects of sarpogrelate hydrochloride on platelet aggregation, and its relation to the release of serotonin and P-selectin Blood Coagul Fibrinol 10 1999 513 519
152. C.G. Nebigil, and L. Maroteaux Functional consequence of serotonin/5-HT2B receptor signaling in heart: role of mitochondria in transition between hypertrophy and heart failure? Circulation 108 2003 902 908
153. C.G. Nebigil, D.-S. Choi, and A. Dierich Serotonin 2B receptor is required for heart development Proc Natl Acad Sci U S A 97 2000 9508 9513
154. C.G. Nebigil, P. Hickel, and N. Messaddeq Ablation of serotonin 5-HT2B receptors in mice leads to abnormal cardiac structure and function Circulation 103 2001 2973 2979
155. 2B receptor in heart leads to abnormal mitochondrial function and cardiac hypertrophy Circulation 107 2003 3223 3229
156. H. Nishio, A. Inoue, and Y. Nakata Binding affinity of sarpogrelate, a new antiplatelet agent, and its metabolite for serotonin receptor subtypes Arch Int Pharmacodyn 331 1996 189 202
157. H. Obata, S. Saito, K. Ishizaki, and F. Goto Antinociception in rat by sarpogrelate, a selective 5-HT(2A) receptor antagonist, is peripheral Eur J Pharmacol 404 2000 95 102
158. T. Ogawa, A. Sugidachi, N. Tanaka, K. Fujimoto, and F. Asai Pharmacological profiles of R-96544, the active form of a novel 5-HT2A receptor antagonist R-102444 Eur J Pharmacol 457 2-3 2002 107 114
159. Y. Ootsuka, and W.W. Blessing 5-Hydroxytryptamine 1A receptors inhibit cold-induced sympathetically mediated cutaneous vasoconstriction in rabbits J Physiol 1 552 Pt 1 2003 303 314
160. M. Orsetti, A. Dellarole, S. Ferri, and P. Ghi Acquisition, retention, and recall of memory after injection of Rs67333, a 5-HT (4) receptor agonist, into the nucleus basalis magnocellularis of the rat Learn Mem 10 5 2003 420 426
161. J.M. Palacois, C. Waeber, D. Hoyer, and G. Mengod Distribution of serotonin receptors Ann N Y Acad Sci 600 1990 36 52
162. K. Palczewski, T. Kumasaka, T. Hori, C.A. Behnke, H. Motoshima, and B.A. Fox Crystal structure of rhodopsin: a G protein-coupled receptor Science 289 5480 2000 739 745
163. A. Pazos, R. Cortes, and J.M. Palacios Quantitative autoradiographic mapping of serotonin receptor in the rat brain: II. Serotonin-2 receptors Brain Res 346 1985 231 249
164. 2A receptor specificity, stereoselectivity and modulation of ritanserin-induced depression of 5-HT contractions in rat-tail artery J Pharm Pharmacol 47 1995 310 316
165. 3 receptor-mediated electrical responses in nodose ganglion neurones and clonal neuroblastoma cells maintained in culture J.R. Fozard P.R. Saxena Serotonin: Molecular Biology, Receptors and Functional Effects 1991 Birkhauser Verlag Basel, Switzerland 84 94
166. D.B. Prichett, A.W.J. Bach, M. Wozny, O. Taleb, R.D. Toso, and J.C. Shih Structure and functional expression of cloned rat serotonin 5HT-2 receptor EMBO J 7 1988 4135 4140
167. N.M. Ramadan, V. Skljarevski, L.A. Phebus, and K.W. Johnson 5-HT1F receptor agonists in acute migraine treatment: a hypothesis Cephalalgia 23 8 2003 776 785
168. H.P. Rang, M.M. Dale, and J.M. Ritter Other peripheral mediators. 5-Hydroxytryptamine and purines H.P. Rang Pharmacology 1999 Churchill Livingstone, Harcourt Brace Edinburgh, UK 168
169. 2 antagonists Jpn J Pharmacol 87 2001 189 194
170. 2 antagonist, AT-1015 (N-[2-[4-(5H-dibenzo[a, d] cyclohepten-5-ylidene)-piperidino]ethyl]-1-formyl-4-piperidinecarboxamide monohydrochloride monohydrate), in the rabbit platelet membrane Biol Pharm Bull 24 2001 1188 1190
171. 2 receptor antagonists Ōyō Yakuri/Pharmacometrics 62 2002 97 103
172. 2 antagonist, on 5-HT-induced endothelium-dependent relaxations in porcine coronary artery Jpn J Pharmacol 89 2002 405 412
173. 2C receptor subtypes by molecular modeling Life Sci 73 2003 193 207
174. D.C. Remy, A.W. Raab, K.E. Rittle, E.L. Engelhardt, A. Scriabine, and V.J. Lotti A comparison of the antiserotonin antihistamine and anticholinergic activity of cyproheptadine with analogs having furan nuclei fused to the 10,11 vinylene bridge J Med Chem 20 1977 836 838
175. B.P. Richardson, and D. Hoyer Selective agonists and antagonists at 5-hydroxytryptamine receptor subtypes R. Paoletti Serotonin: From Cell Biology to Pharmacology and Therapeutics 1990 Kluwer Academic Publishing Dordrecht, The Netherlands 265 276
176. B.P. Richardson, G. Engel, P. Donatsch, and P.A. Stadler Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs Nature (Lond) 316 1985 113 126
177. 6 receptor antagonist J Med Chem 46 2003 1273 1276
178. A. Rivkin Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review Clin Ther 25 7 2003 1952 1974
179. 2A receptor Mol Pharmacol 64 5 2003 1239 1250
180. B.L. Roth Multiple serotonin receptors: clinical and experimental aspects Ann Clin Psychiatry 6 1994 67 78
181. 3H]ketanserin recognition sites in rat striatum J Neurochem 49 1987 1833 1838
182. B.L. Roth, M. Shoham, M.S. Choudhary, and N. Khan Identification of conserved aromatic residues essential for agonist binding and second messenger production at 5-hydroxytryptamine2A receptors Mol Pharmacol 52 1997 259 267
183. B.L. Roth, D.L. Willins, K. Kristiansen, and W.K. Kroeze 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine 2C): where structure meets function Pharmacol Ther 79 1998 231 257
184. M. Ruth, C. Finizia, L. Cange, and L. Lundell The effect of mosapride on oesophageal motor function and acid reflux in patients with gastro-oesophageal reflux disease Eur J Gastroenterol Hepatol 15 10 2003 1115 1121
185. L. Salle, P. Eftekhari, M. Aupart, P. Cosnay, J. Hoebeke, and J.A. Argibay Inhibitory activity of antibodies against the human atrial 5-HT(4)receptor J Mol Cell Cardiol 33 3 2001 405 417
186. 1C receptor subtypes Biochem Biophys Res Commun 181 1991 1449 1478
187. E. Sanders-Bush, and S.T. Mayer 5-hydroxytryptamine (serotonin) receptor agonists and antagonists J.G. Hardman Goodman and Gilman's The Pharmacological Basis of Therapeutics 9th ed. 1996 MacGraw-Hill New York 249
188. P.A. Sargent, A.L. Sharpley, C. Williams, E.M. Goodall, and P.J. Cowen 5-HT2C receptor activation decreases appetite and body weight in obese subjects Psychopharmacology (Berl) 133 3 1997 309 312
189. 2-receptor antagonist, improves the coronary artery microcirculation in coronary artery disease Clin Cardiol 25 2002 28 32
190. P.R. Saxena, and C.M. Villalon Cardiovascular effects of serotonin agonists and antagonists J Cardiovasc Pharmacol 15 1990 S17 S34
191. P.R. Saxena, and C.M. Villalon 5-Hydroxytryptamine: a chameleon in the heart Trends Pharmacol Sci 12 1991 223 227
192. P.R. Saxena, P. De Vries, and C.M. Villalon 5-HT1-like receptors: a time to bid goodbye Trends Pharmacol Sci 19 8 1998 311 316
193. S.M. Schwartz, and M. Reidy Common mechanisms of proliferation of smooth muscle in atherosclerosis and hypertension Hum Pathol 18 1987 240 247
194. S.M. Schwartz, G.R. Campbell, and J.H. Campbell Replication of smooth muscle cells in vascular disease Circ Res 58 1986 427 444
195. 1D receptors Naunyn-Schmiedeberg's Arch Pharmacol 340 1989 135 138
196. Y. Setoguchi, T. Ohnuki, M. Rashid, T. Nakamura, K. Hattori, and T. Nagatomo Effects of chronic administration of sarpogrelate on systolic blood pressure of spontaneously hypertensive rats (SHR): comparison with quinapril Pharmacology 64 2 2002 71 75
197. D.A. Shapiro, K. Kristiansen, W.K. Kroeze, and B.L. Roth Differential modes of agonist binding to 5-hydroxytryptamine2A serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5 Mol Pharmacol 58 5 2000 877 886
198. D.A. Shapiro, K. Kristiansen, D.M. Weiner, W.K. Kroeze, and B.L. Roth Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6 J Biol Chem 277 13 2002 11441 11449
199. S.K. Sharma, P. Zahradka, D. Chapman, H. Kumamoto, N. Takeda, and N.S. Dhalla Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate J Pharmacol Exp Ther 290 1999 1475 1481
200. A.J. Sleight, F.G. Boess, M. Bos, B. Levet-Trafit, C. Riemer, and A. Bourson Characterization of Ro 04-6790 and Ro 63-0563: potent and selective antagonists at human and rat 5-HT6 receptors Br J Pharmacol 124 3 1998 556 562
201. R.S. Sparkes, N. Lan, I. Klisak, T. Mohandas, A. Diep, and T. Kojis Assignment of a serotonin 5HT-2 receptor gene (HTR2) to human chromosome 13q14-q21 and mouse chromosome 14 Genomics 9 1991 461 465
202. J. Sprouse, L. Reynolds, X. Li, J. Braselton, and A. Schmidt 8-OH-DPAT as a 5-HT7 agonist: Phase shifts of the circadian biological clock through increases in camp production Neuropharmacology 46 1 2004 52 62
203. D.W. Steyn, and H.J. Odendaal Serotonin antagonism and serotonin antagonists in pregnancy: role of ketanserin Obstet Gynecol Surv 55 9 2000 582 589
204. D.W. Steyn, and H.J. Odendaal Blood pressure patterns in pregnant patients on oral ketanserin Cardiovasc J S Afr 12 2 2001 82 87
205. N. Takuwa, M. Ganz, Y. Takuwa, R.B. Sterzel, and H. Rasmussen Studies of the mitogenic effect of serotonin in rat renal mesangial cells Am J Physiol 257 1989 F431 F439
206. H. Tamir, S.C. Hsiung, P.Y. Yu, K.P. Liu, M. Adlersberg, and E.A. Nunez Serotonergic signaling between thyroid cells: Protein kinase C and 5HT2 receptors in the secretion and action of serotonin Synapse 12 1992 155 168
207. 2 receptors Atherosclerosis 132 1997 139 143
208. T. Tanaka, M. Fijita, I. Nakae, S. Tamaki, K. Hasegawa, and Y. Kihara Improvement of exercise capacity by sarpogrelate as a result of augmented collateral circulation in patients with effort angina J Am Coll Cardiol 32 1998 1982 1986
209. D.P. Taylor Serotonin agents in anxiety P.M. Whitaker-Azmitia S.J. Peroutka The Pharmacology of Serotonin 1990 New York Academy of Sciences New York 545 557
210. R.M. Temsah, H. Kumamoto, N. Takeda, and N.S. Dhalla Sarpogrelate diminishes changes in energy stores and ultrastructure of the ischemic-reperfused rat heart Can J Physiol Pharmacol 79 2001 761 767
211. J.A. Terron GR127935 is a potent antagonist of the 5-HT1-like receptor mediating contraction in the canine coronary artery Eur J Pharmacol 300 1-2 1996 109 112
212. J.A. Terron, and A. Falcon-Neri Pharmacological evidence for the 5-HT7 receptor mediating smooth muscle relaxation in canine cerebral arteries Br J Pharmacol 127 3 1999 609 616
213. D.R. Thomas, and J.J. Hagan 5-HT7 receptors Curr Drug Targets CNS Neurol Disord 3 1 2004 81 90
214. N. Toda, and T. Okamura Comparison of the response to 5-carboxamidotryptamine and serotonin in isolated human, monkey and dog coronary arteries J Pharmacol Exp Ther 253 1990 676 682
215. C. Tournois, V. Mutel, P. Manivet, J.M. Launay, and O. Kellermann Cross-talk between 5-hydroxytryptamine receptors in a serotonergic cell line: involvement of arachidonic acid metabolism J Biol Chem 273 1998 17498 17503
216. 1A receptor-related anxiolytics Trends Pharmacol Sci 8 1987 432 437
217. M.D. Tricklebank The behavioural response to 5-HT receptor agonists and subtypes of the central 5-HT receptor Trends Pharmacol Sci 6 1985 403 407
218. 3H]ketanserin for serotonin-2 receptor in the rabbit platelet J Pharmacobio-Dyn 14 1991 461 466
219. D.N. Umrani, D.N. Bodiwala, and R.K. Goyal Effect of sarpogrelate on altered STZ-diabetes induced cardiovascular responses to 5-hydroxytryptamine in rats Mol Cell Biochem 249 1-2 2003 53 57
220. A. Usui, Y. Takagi, Y. Ohara, O. Kawaguchi, T. Watanabe, and Y. Ueda Sarpogrelate reduces mechanical hemolysis in patients with heart valve prostheses Jpn J Thorac Cardiovasc Surg 48 2000 769 774
221. R.W. Van den Broek, A. MaassenVanDenBrink, P.G. Mulder, A.J. Bogers, C.J. Avezaat, and G.W. John Comparison of contractile responses to domitriptan and sumatriptan in the human middle meningeal and coronary arteries Eur J Pharmacol 443 1-3 2002 125 132
222. P. Vanhoutte, A. Amery, W. Birkenhager, A. Brekenridge, F. Buhler, and A. Distler Serotonergic mechanisms in hypertension. Focus on the effects of ketanserin Hypertension 11 1988 111 133
223. 2 serotonergic receptor J Pharmacol Exp Ther 218 1981 217 230
224. K. Viekenes, M. Farstad, and J.E. Nordrehaung Serotonin is associated with coronary artery disease and cardiac events Circulation 100 1999 483 489
225. C.M. Villalon, and P.R. Saxena Serotonin receptors as cardiovascular targets Drug Disc Today 2 1997 294 300
226. C.M. Villalon, D. Centurion, G. Rabelo, P. de Vries, P.R. Saxena, and A. Sanchez-Lopez The 5-HT1-like receptors mediating inhibition of sympathetic vasopressor outflow in the pithed rat: operational correlation with the 5-HT1A, 5-HT1B and 5-HT1D subtypes Br J Pharmacol 124 5 1998 1001 1011
227. C.M. Villalon, A. Sanchez-Lopez, D. Centurion, and P.R. Saxena Unravelling the pharmacological profile of the canine external carotid vasodilator '5-HT1-like' receptors: coexistence of sympatho-inhibitory 5-HT1B and postjunctional 5-HT7 receptors Naunyn-Schmiedeberg's Arch Pharmacol 363 1 2001 73 80
228. C. Waeber, M.M. Dietl, D. Hoyer, A. Probst, and J.M. Palacios Visualization of a novel seorotonin recognition site (5-HT1D) in the human brain by autoradiography Neurosci Lett 88 1988 11 16
229. 2A receptor Ann N Y Acad Sci 861 1998 162 168
230. S.W. Watts The development of enhanced arterial serotonergic hyperresponsiveness in mineralocorticoid hypertension J Hypertens 16 1998 811 822
231. P. Wester, W.D. Dietrich, R. Prado, B.D. Watson, and M.Y. Globus Serotonin release into plasma during common carotid artery thrombosis in rats Stroke 23 1992 870 875
232. B.D. Wilcox, L. Rydelek-Fitzgerald, and J.J. Jeffrey Regulation of Collagenase gene expression by serotonin and progesterone in rat uterine smooth muscle cells J Biol Chem 267 1992 20752 20757
233. M.L. Woolley, C.A. Marsden, and K.C. Fone 5-HT6 receptors Curr Drug Targets CNS Neurol Disord 3 1 2004 59 79
234. 2C receptor: complete cDNA, genomic structure, and alternatively spliced variant Genomics 35 1996 551 561
235. Xin, H. B., Zhang, B. H., Shen, H. J., Zhongguo Yao, Li Xue Bao (1994). Protective effects of cyproheptadine on myocardial reperfusion injury in isolated rat hearts. 15(3), 253-257.
236. Y.C. Xu, K.W. Johnson, L.A. Phebus, M. Cohen, D.L. Nelson, and K. Schenck N-[3-(2-Dimethylaminoethyl)-2-methyl-1H-indol-5-yl]-4-fluorobenzamide: a potent, selective, and orally active 5-HT(1F) receptor agonist potentially useful for migraine therapy J Med Chem 44 24 2001 4031 4034
237. J. Xu, B. Jian, R. Chu, Z. Lu, Q. Li, and J. Dunlop Serotonin mechanisms in heart valve disease: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells Am J Pathol 161 6 2002 2209 2218
238. T. Yamashita, K. Kitamori, M. Hashimoto, S. Watanabe, J.C. Giddings, and J. Yamamoto Conjunctive effects of the 5HT(2) receptor antagonist, sarpogrelate, on thrombolysis with modified tissue plasminogen activator in different laser-induced thrombosis models Haemostasis 30 2000 321 332
239. W. Yang, K. Chen, N.C. lan, T.K. Gallaher, and J.C. Shih Gene structure and expression of the mouse 5-HT2 receptor J Neurosci Res 33 1992 196 204
240. 1A receptor in rat and guinea-pig hippocampal membranes Eur J Pharmacol 137 1987 293 294
241. 1C receptor contains eight hydrophobic domains and is X-linked Brain Res Mol Brain Res 11 1991 143 149
242. S. Yusuf, N. Al-Saady, and A.J. Camm 5-Hydroxytryptamine and atrial fibrillation: how significant is this piece in the puzzle? J Cardiovasc Electrophysiol 14 2003 209 214